- Details
- Description
-
Packaging Size21t
-
Strength200mg
-
CompositonSavolitinib
-
Treatmentnon-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations
-
FormTablet
-
BrandOrpathys (沃瑞沙)
-
Quantity Unit200mg*21t
-
ManufacturerHUTCHMED, china
About Savolitinib
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumours. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.
- Savolitinib sold under the brand name Orpathys .
- Savolitinib sold under the brand name 沃瑞沙 in china.
Approval
June 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.
Dosage
Recommended dose and administration
For patients weighing ≥50 kg, the recommended starting dose is 600 mg, taken orally once daily until disease progression or intolerable toxicity occurs.
For patients weighing <50 kg, the recommended starting dose is 400 mg, taken orally once daily until disease progression or intolerable toxicity occurs.
It is recommended to take this product immediately after a meal at the same time every day.
Dose adjustment
Doctors should closely monitor patients during medication and adjust medication according to individual patient safety and tolerability, including suspending this product, reducing the dose, or permanently discontinuing this product.
